Intervacc AB (IVACC) AI Stock Analysis

• Market Cap: kr343.54M
• Dividend Yield: N/A
• Average Volume (3M): 900.55K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.93
• Revenue Growth: 47.06%
• EPS Growth: 33.86%
• Country: SE
• Employees: 15
• Sector: Healthcare
• Sector Strength: 58
• Industry: Biotechnology
• EPS (TTM): -0.08
• Shares Outstanding: 340,813,200
• 10 Day Avg. Volume: 402,209
• 30 Day Avg. Volume: 900,555
• PEG Ratio: -0.21
• Price to Book (P/B): 0.59
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -6.82
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 42 Neutral
• Price Target: ―

Intervacc AB's overall stock score is primarily impacted by its significant financial challenges, particularly ongoing net losses and negative cash flows. The technical analysis provides a mixed picture, with some potential resistance ahead. Valuation concerns are exacerbated by a negative P/E ratio and lack of dividend yield. Strategic improvements in financial performance are crucial for enhancing the stock's prospects.

Intervacc AB Business Overview & Revenue Model

Company Description

Intervacc AB (IVACC) is a Swedish biotechnology company that specializes in the development of novel vaccines for animals. Operating primarily within the veterinary health sector, the company focuses on creating innovative solutions to combat infectious diseases affecting livestock and companion animals. Their core products include Strangvac, a vaccine developed to protect horses against strangles, a highly contagious equine disease.

How the Company Makes Money

Intervacc AB generates revenue primarily through the sale and distribution of its veterinary vaccines. The company's main revenue stream comes from Strangvac, which is marketed and sold to veterinary clinics, horse owners, and equine organizations. Intervacc also engages in strategic partnerships and collaborations with veterinary pharmaceutical companies for the distribution and co-development of vaccines, further contributing to its earnings. Additionally, the company may receive funding and grants for its research and development efforts from governmental or industry sources, supporting its ongoing innovation and product development initiatives.

Intervacc AB Financial Statement Overview

Summary

Intervacc AB faces significant financial challenges, primarily driven by consistent net losses and negative cash flows. The balance sheet shows strong equity and no debt, but the negative profitability and cash flow trends pose substantial risks. Strategic improvements in revenue generation and cost management are essential to improve financial health.

Income Statement

Intervacc AB's income statement reveals significant challenges. The company experienced a negative gross profit margin and substantial net losses in recent years, indicating difficulties in covering production costs and achieving profitability. Revenue growth has been inconsistent, with a significant decline in recent periods, which poses a risk to future financial stability.

Balance Sheet

The balance sheet of Intervacc AB shows a strong equity base with no debt, indicating low financial leverage and reduced risk of insolvency. However, the decline in total assets over the years suggests a reduction in company resources. The high equity ratio is a positive sign of financial stability, though it is offset by diminishing assets.

Cash Flow

Intervacc AB's cash flow statements highlight ongoing operating cash flow deficits, which could strain liquidity. Despite the negative free cash flow, the absence of financial debt provides some relief. Nonetheless, the company needs to enhance its cash generation capabilities to sustain operations and fund growth.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
11.79M	8.02M	9.68M	5.24M	4.78M
	Gross Profit
-3.53M	-13.81M	3.37M	6.25M	4.64M
	EBIT
-77.28M	-93.58M	-64.41M	-29.39M	-25.68M
	EBITDA
-58.75M	-68.98M	-57.73M	-23.15M	-19.39M
	Net Income Common Stockholders
-75.52M	-102.85M	-64.16M	-29.38M	-25.60M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
34.40M	88.34M	45.70M	115.71M	164.25M
	Total Assets
187.32M	259.61M	265.04M	329.39M	355.28M
	Total Debt
0.00	181.00K	322.00K	433.00K	383.00K
	Net Debt
-34.40M	-88.16M	-45.38M	-115.28M	-163.87M
	Total Liabilities
24.99M	21.68M	14.88M	21.14M	17.67M
	Stockholders Equity
162.33M	237.93M	250.16M	308.25M	337.61M
Cash Flow		Free Cash Flow
-53.90M	-47.94M	-75.92M	-48.67M	-31.50M
	Operating Cash Flow
-53.20M	-45.83M	-69.79M	-25.46M	-20.08M
	Investing Cash Flow
-706.00K	-2.11M	-6.13M	-23.13M	-11.27M
	Financing Cash Flow
-36.00K	90.58M	5.91M	50.00K	143.06M

Intervacc AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.08
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:IVACC, the sentiment is Negative. The current price of 1.08 is above the 20-day moving average (MA) of 1.08, above the 50-day MA of 1.05, and below the 200-day MA of 1.61, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 38.90 is Neutral, neither overbought nor oversold. The STOCH value of 25.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:IVACC.

Intervacc AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
XBRANE	54 Neutral	kr383.05M	―	-47.73%	―	45.52%	93.35%
Sector *	54 Neutral	$5.41B	3.27	-45.10%	3.29%	16.81%	0.02%
IMMU	44 Neutral	€338.03M	―	-18.79%	―	―	21.85%
IVACC	42 Neutral	kr343.54M	―	-24.61%	―	47.06%	33.86%
ONCO	40 Underperform	kr321.12M	―		―	1.72%	32.54%
GUARD	32 Underperform	kr353.94M	―	-205.65%	―	―	24.25%
CANTA	31 Underperform	kr270.99M	―	-167.55%	―	―	46.67%